Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature-Reference-Cited by-同舟云学术

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature

Published:2016-07-19 Issue:40 Volume:8 Page:68950-68963
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Alvarez-Twose Iván¹²,Matito Almudena¹²,Morgado José Mário¹²,Sánchez-Muñoz Laura¹²,Jara-Acevedo María³²,García-Montero Andrés³²,Mayado Andrea³²,Caldas Carolina³²,Teodósio Cristina⁴,Muñoz-González Javier Ignacio³²,Mollejo Manuela⁵²,Escribano Luis³²,Orfao Alberto³²

Affiliation:

1. Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain

2. Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain

3. Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría, University of Salamanca, Salamanca, Spain

4. Department of Immunology, Erasmus Medical Center, University of Rotterdam, Rotterdam, The Netherlands

5. Department of Pathology, Hospital Virgen de la Salud, Toledo, Spain

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Mastocytosis: State of the Art;Current Hematologic Malignancy Reports;2024-08-27

2. Nouveaux critères diagnostiques des mastocytoses : des progrès mais encore des interrogations;Bulletin de l'Académie Nationale de Médecine;2024-06

3. SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis;Clinical Lymphoma Myeloma and Leukemia;2024-06

4. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee;Leukemia;2024-03-12

5. Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis;Cancers;2024-01-30